$Inventiva(IVA.US)$Inventiva Receives Recommendation From The 4th Scheduled Data Monitoring Committee Meeting Of The NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH Benzinga· The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in t...
$Inventiva(IVA.US)$SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-New Enterprise Associates 17, L.P.(10.7%),NEA Partners 17, L.P.(10.7%), etc. SEC announcement· May 3 21:27
$Inventiva(IVA.US)$Inventiva (NASDAQ:IVA) reported a Phase 2 study of its drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes.
$Inventiva(IVA.US)$Inventiva Resumes Screening In NATiV3, Phase III, Clinical Trial Evaluating Lanifibranor In NASH Benzinga· 2 mins ago Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. Screening of patients is resuming in sites operating under central IRB in the US. Other sites and countries are expected to resume screening and randomization activities progr...
Inventiva股票討論區
Benzinga·
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in t...
SEC announcement· May 3 21:27
Benzinga· 2 mins ago
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
Screening of patients is resuming in sites operating under central IRB in the US.
Other sites and countries are expected to resume screening and randomization activities progr...
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
$CohBar(CWBR.US)$ 0.64
$Onfolio(ONFO.US)$ 0.48
$SenesTech(SNES.US)$ 1.1
close watch SOUN
$美國超微公司(AMD.US)$ $Bit Digital(BTBT.US)$ $Bitdeer Technologies(BTDR.US)$ $Chewy(CHWY.US)$ $DoorDash(DASH.US)$ $Inventiva(IVA.US)$ $NeoVolta(NEOV.US)$ $Eneti(NETI.US)$ $Orchestra BioMed(OBIO.US)$ $Panbela Therapeutics(PBLA.US)$ $Lordstown Motors(RIDE.US)$ $Sientra(SIEN.US)$ $SoundHound AI(SOUN.US)$ $天成金匯(TCJH.US)$ $豐田汽車(TM.US)$
暫無評論